» Articles » PMID: 35013906

Overexpression of ORX or MCH Protects Neurological Function Against Ischemic Stroke

Overview
Journal Neurotox Res
Publisher Springer
Specialty Neurology
Date 2022 Jan 11
PMID 35013906
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, orexin (ORX) and melanin-concentrating hormone (MCH) have been demonstrated to exert neuroprotective roles in cerebral ischemia. Hence, this study investigated the regulatory function of ORX and MCH in neurological function following ischemic stroke and explored the molecular mechanism underlying these functions. A rat model of ischemic stroke was developed by middle cerebral artery occlusion (MCAO), and Longa scoring was employed to evaluate the degree of neurological function deficit. The expression patterns of ORX and MCH were examined by real-time polymerase chain reaction in the brain tissues of rats with ischemic stroke induced by middle cerebral artery occlusion (MCAO). Moreover, electroencephalography (EEG) analysis and high-performance liquid chromatography (HPLC) were respectively performed to detect rapid-eye movement (REM) sleep, the glutamate (Glu) uptake, and the expression of γ-aminobutyric acid B receptor (GABA). Immunoblotting was performed to test the levels of autophagic markers LC3, BECLIN-1, and p62. Immunohistochemistry (IHC) staining and TUNEL assays were respectively used to assess the autophagy and neuronal apoptosis. Results demonstrated that ORX and MCH were lowly expressed in brain of rats with ischemic stroke. ORX or MCH overexpression decreased neuronal apoptosis and autophagy, and improved the sleep architecture of post-stroke rats, while rescuing Glu uptake and GABA expression. ORX or MCH upregulation exerted protective effects on neurological function. Taken together, ORX and/or MCH protect against ischemic stroke in a rat model, highlighting their value as targets for the clinical treatment of ischemic stroke.

Citing Articles

Inclusion of hypocretin-1 improved performance of poor sleep quality prediction for elderly patients with acute ischemic stroke: a prospective cohort study.

Fu T, Zhang W, Guo R, He S, Yu S, Wang H Front Aging Neurosci. 2025; 16():1509846.

PMID: 39839304 PMC: 11747788. DOI: 10.3389/fnagi.2024.1509846.

References
1.
Clark I, Vissel B . Inflammation-sleep interface in brain disease: TNF, insulin, orexin. J Neuroinflammation. 2014; 11:51. PMC: 3994460. DOI: 10.1186/1742-2094-11-51. View

2.
Denk H, Stumptner C, Abuja P, Zatloukal K . Sequestosome 1/p62-related pathways as therapeutic targets in hepatocellular carcinoma. Expert Opin Ther Targets. 2019; 23(5):393-406. DOI: 10.1080/14728222.2019.1601703. View

3.
Flores A, Saravia R, Maldonado R, Berrendero F . Orexins and fear: implications for the treatment of anxiety disorders. Trends Neurosci. 2015; 38(9):550-9. DOI: 10.1016/j.tins.2015.06.005. View

4.
Gonzalez J, Iordanidou P, Strom M, Adamantidis A, Burdakov D . Awake dynamics and brain-wide direct inputs of hypothalamic MCH and orexin networks. Nat Commun. 2016; 7:11395. PMC: 4844703. DOI: 10.1038/ncomms11395. View

5.
Harada S, Yamazaki Y, Tokuyama S . Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor. J Pharmacol Exp Ther. 2012; 344(1):276-85. DOI: 10.1124/jpet.112.199604. View